Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2)

Last updated: May 11, 2022
Sponsor: D'Or Institute for Research and Education
Overall Status: Completed

Phase

2/3

Condition

Inflammation

Covid-19

Treatment

N/A

Clinical Study ID

NCT04800224
31099320.6.0000.0049
  • Ages > 18
  • All Genders

Study Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Among candidate adjunct treatment options, propolis, produced by honey bees from bioactive plant exudates, has shown potential against viral targets and has demonstrated immunoregulatory properties.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Older than 18 years;
  • Diagnosis of coronavirus infection confirmed by polymerase chain reaction - reversetranscriptase testing;
  • Symptoms started within 14 days of the randomization date

Exclusion

Exclusion Criteria:

  • Pregnant or lactating women;
  • Known hypersensitivity to propolis;
  • Propolis use less than 30 days from the randomization date;
  • Active cancer;
  • Human immunodeficiency virus carriers;
  • Patients undergoing transplantation of solid organs or bone marrow or who were usingimmunosuppressive medications;
  • Bacterial infection at randomization, sepsis or septic shock related to bacterialinfection at randomization;
  • Impossibility of using the medication orally or by nasoenteral tube;
  • Known hepatic failure or advanced heart failure (New York Heart Association [NYHA]class III or IV).
  • End Stage Renal Disease (ESRD).

Study Design

Total Participants: 200
Study Start date:
April 12, 2021
Estimated Completion Date:
July 30, 2021

Study Description

To evaluate the efficacy and safety of oral propolis as an adjunct treatment for SARS-CoV-2 infection, we designed a randomized, double-blind, placebo-controlled trial (Bee-Covid2) (The Use of Brazilian Green Propolis Extract (EPP-AF®) in Patients Affected by COVID-19).

Connect with a study center

  • Hospital Sao Rafael

    Salvador, BA 41820340
    Brazil

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.